Study finds, Non-infectious uveitis affecting the posterior
Prevention of non-infectious uveitis of the posterior segment (NIU-PS) recurrence using 0.2 microg/day fluocinolone acetonide implant (FAi) was assessed over 3 years. Outcomes for FAi-treated and fellow eyes with NIU-PS were compared, to evaluate FAi versus conventional treatment strategies.

Eligible subjects had more than 1-year recurrent NIU-PS history and either more than 2 separate recurrences requiring treatment, or corticosteroid therapy (systemic or ocular) in the 12 months preceding study entry. Bilateral disease was present and analysed in 59/87 FAi-treated participants. Recurrence rates, best-corrected visual acuity (BCVA) changes, cataract surgery, intraocular pressure (IOP) events and adjunctive medication use were compared for FAi-treated and fellow eyes.

--Over 36 months, more FAi-treated than fellow eyes remained recurrence-free (28.8% vs. 5.1%).

--FAi-treated eyes gained +9.6 letters BCVA, versus a loss of -4.4 in fellow eyes.

--Systemic medications were given to 42.4% of subjects. Intra/periocular adjunctive injections were lower in FAi-treated than fellow eyes; topical corticosteroid use was also lower in FAi-treated than fellow eyes (27.1% vs 52.5%).

--IOP-related events occurred at similar rates in both FAi-treated and fellow eyes, excepting IOP-lowering surgery (5.1% vs. 15.3%).

--Cataract surgery occurred in 72.0% of FAi-treated and 37.0% of fellow eyes.

Conclusively, continuous, low dose corticosteroid with 0.2 microg/day FAi in participants with bilateral NIU-PS reduced recurrence and medication needs and improved vision over 36 months. This provides superior protection against ocular inflammation than a reactive strategy by employing conventional care.